U.S. Emerging Osteoporosis Therapeutics Markets
U.S. Emerging Osteoporosis Therapeutics Markets
RELEASE DATE
26-Apr-2002
26-Apr-2002
REGION
North America
North America
Research Code: A176-01-00-00-00
SKU: HC00827-NA-MR_04524
$2,450.00
Special Price $1,837.50 save 25 %
In stock
SKU
HC00827-NA-MR_04524
Description
This report gives detailed information about the U.S. osteoporosis market participants, revenue forecasts, market shares, projected prevalence of disease and therapeutic options, according to product class, namely estrogen replacement therapy, biphosphonates, calcitonin, selective estrogen receptor modulators and other emerging osteoporosis therapies. Key market and technology trends are discussed relative to the future of the market.
Table of Contents
Executive Summary
- Executive Summary
Overview
- Scope and Segmentation
- Disease Definition And Pathogenesis
- Types Of Osteoporosis
- Risk Factors
- Symptoms
- Diagnosis
- Prevention And Treatment
- Cost Of Osteoporotic Fractures
- Challenges
- Market Drivers
- Market Restraints
Market Dynamics
- Demand Analysis
- Market and Technology Trends
Strategic Recommendations
- Strategies Overview
- Strategic Recommendations for Market Challenge 1
- Strategic Recommendations for Market Challenge 2
- Strategic Recommendations for Market Challenge 3
Frost & Sullivan Market Engineering Awards
- Technology Innovation Award: NPS Pharmaceuticals
- Strategic Alliance Innovation Award: Emisphere Technologies
- Technology Leadership Award: Eli Lilly And Company
- Business Development Strategy Award: The Alliance For Better Bone Health
- Product Line Strategy Award: Wyeth
Overview
Forecasts and Trends
Competitive Analysis
Overview
Forecasts and Trends
Competitive Analysis
Overview
Forecasts and Trends
Competitive Analysis
Overview
Forecasts and Trends
Competitive Analysis
Overview
Forecasts and Trends
Competitive Analysis
Popular Topics
This report gives detailed information about the U.S. osteoporosis market participants, revenue forecasts, market shares, projected prevalence of disease and therapeutic options, according to product class, namely estrogen replacement therapy, biphosphonates, calcitonin, selective estrogen receptor modulators and other emerging osteoporosis therapies. Key market and technology trends are discussed relative to the future of the market.
No Index | Yes |
---|---|
Podcast | No |
Industries | Healthcare |
WIP Number | A176-01-00-00-00 |
Is Prebook | No |